Determinants of biological drug survival in rheumatoid arthritis: Evidence from a hungarian rheumatology center over 8 years of retrospective data

ClinicoEconomics and Outcomes Research

Volumn 9, Issue , 2017, Pages 139-147

  Brodszky, Valentin ^a   Bíró, Anikó ^a,b   Szekanecz, Zoltán ^c   Soós, Boglárka ^c   Baji, Petra ^a   Rencz, Fanni ^a,d   Tóthfalusi, László ^e   Gulácsi, László ^a   Péntek, Márta ^a,f  

^a Institute of Data Analytics and Information Systems   (Hungary)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF DEBRECEN   (Hungary)

^d SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^e SEMMELWEIS UNIVERSITY   (Hungary)

^f Pest Megyei Flor Ferenc Korhaz   (Hungary)

Author keywords

Biologicals; Drug survival; Registry; Rheumatoid arthritis; Switch

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG SURVIVAL; DRUG WITHDRAWAL; FEMALE; HUMAN; HUNGARY; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 85015860070     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S124381     Document Type: Article

References (39)

1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-2038.
2. Taylor PC, Moore A, Vasilescu R, Alvir J, Tarallo M. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: A current perspective. Rheumatol Int. 2016;36(5):685-695.
3. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3-15.
4. Sullivan SD, Alfonso-Cristancho R, Carlson J, Mallya U, Ringold S. Economic consequences of sequencing biologics in rheumatoid arthritis: a systematic review. J Med Econ. 2013;16(3):391-396.
5. Gvozdenović E, Koevoets R, Langenhoff J, Allaart CF, Landewé RB. Comparison of characteristics of international and national databases for rheumatoid arthritis: A systematic literature review. Scand J Rheumatol. 2014;43(5):349-355.
6. Koncz T, Pentek M, Brodszky V, Ersek K, Orlewska E, Gulacsi L. Adherence to biologic DMARD therapies in rheumatoid arthritis. Expert Opin Biol Ther. 2010;10(9):1367-1378.
7. Fidder HH, Singendonk MM, van der Have M, Oldenburg B, van Oijen MG. Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn’s disease and rheumatoid arthritis: results of a systematic review. World J Gastroenterol. 2013;19(27):4344-4350.
8. López-González R, León L, Loza E, Redondo M, Garcia de Yébenes MJ, Carmona L. Adherence to biologic therapies and associated factors in rheumatoid arthritis, spondyloarthritis and psoriatic arthritis: A systematic literature review. Clin Exp Rheumatol. 2015;33(4):559-569.
9. Leon L, Rodriguez-Rodriguez L, Rosales Z, et al. Long-term drug survival of biological agents in patients with rheumatoid arthritis in clinical practice. Scand J Rheumatol. 2016:45(6):456-460.
10. Gulácsi L, Rencz F, Poór G, et al. Patients’ access to biological therapy in chronic inflammatory conditions; per capita GDP does not explain the intercountry differences. Ann Rheum Dis. 2016;75(5):942-943.
11. Boncz I, Sebestyén A. Financial deficits in the health services of the UK and Hungary. Lancet. 2006;368(9539):917-918.
12. Pease C, Pope JE, Truong D, et al. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy. Semin Arthritis Rheum. 2011;41(1):81-89.
13. Putrik P, Ramiro S, Kvien TK, Sokka T, Uhlig T, Boonen A; Equity in Clinical Eligibility Criteria for RA treatment Working Group. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country’s wealth? Ann Rheum Dis. 2014;73(11):2010-2021.
14. Péntek M, Poór G, Wiland P, et al. Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries. Eur J Health Econ. 2014;15 Suppl 1:S35-S43.
15. Rencz F, Kemény L, Gajdácsi JZ, et al. Use of biologics for psoriasis in Central and Eastern European countries. J Eur Acad Dermatol Venereol. 2015;29(11):2222-2230.
16. Rencz F, Péntek M, Bortlik M, et al. Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe. World J Gastroenterol. 2015;21(6):1728-1737.
17. Kádár G, Balázs E, Soós B, et al. Disease activity after the discontinuation of biological therapy in inflammatory rheumatic diseases. Clin Rheumatol. 2014;33(3):329-333.
18. Laki J, Mónok G, Pálosi M, Gajdácsi JZ. Economical aspect of biological therapy in inflammatory conditions in Hungary. Expert Opin Biol Ther. 2013;13(3):327-337.
19. Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5-14.
20. Brodszky V, Baji P, Balogh O, Péntek M. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur J Health Econ. 2014;15(Suppl 1):S65-S71.
21. Jha A, Upton A, Dunlop WC, Akehurst R. The budget impact of biosimilar infliximab (Remsima®) for the treatment of autoimmune diseases in five European countries. Adv Ther. 2015;32(8):742-756.
22. van Riel PL, Renskers L. The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34 Suppl 101(5): 40-44.
23. Yeaw J, Watson C, Fox KM, Schabert VF, Goodman S, Gandra SR. Treatment patterns following discontinuation of adalimumab, etanercept, and infliximab in a US managed care sample. Adv Ther. 2014;31(4): 410-425.
24. Meissner B, Trivedi D, You M, Rosenblatt L. Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting. J Med Econ. 2014;17(4):259-265.
25. Bonafede M, Fox KM, Watson C, Princic N, Gandra SR. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Adv Ther. 2012;29(8):664-674.
26. Ogale S, Hitraya E, Henk HJ. Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord. 2011;12:204.
27. Li P, Blum MA, Von Feldt J, Hennessy S, Doshi JA. Adherence, discontinuation, and switching of biologic therapies in medicaid enrollees with rheumatoid arthritis. Value Health. 2010;13(6):805-812.
28. Chatzidionysiou K, Askling J, Eriksson J, Kristensen LE, van Vollenhoven R. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. Ann Rheum Dis. 2015;74(5):890-896.
29. Lequerré T, Farran É, Ménard JF, et al. Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: an observational retrospective study of 72 rheumatoid arthritis switchers. Joint Bone Spine. 2015;82(5):330-337.
30. Huizinga TW, Conaghan PG, Martin-Mola E, et al. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis. 2015;74(1):35-43.
31. Smolen JS, Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol. 2015;11(5):276-289.
32. Souto A, Maneiro JR, Gómez-Reino JJ. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology (Oxford). 2016;55(3):523-534.
33. Gomez-Reino JJ, Carmona L; BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther. 2006;8(1):R29.
34. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ; British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second antitumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum. 2007; 56(1):13-20.
35. Martínez-Santana V, González-Sarmiento E, Calleja-Hernández M, Sánchez-Sánchez T. Comparison of drug survival rates for tumor necrosis factor antagonists in rheumatoid arthritis. Patient Prefer Adherence. 2013;7:719-727.
36. Buch MH, Rubbert-Roth A, Ferraccioli G. To switch or not to switch after a poor response to a TNFα blocker? It is not only a matter of ACR20 OR ACR50. Autoimmun Rev. 2012;11(8):558-562.
37. Emery P, Gottenberg JE, Rubbert-Roth A, et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis. 2015;74(6):979-984.
38. Hishitani Y, Ogata A, Shima Y, et al. Retention of tocilizumab and antitumour necrosis factor drugs in the treatment of rheumatoid arthritis. Scand J Rheumatol. 2013;42(4):253-259.
39. Koutsianas C, Thomas K, Hatzara C, et al. FRI0160 comparative drug survival of different non-anti-TNF IV biologics after anti-TNF failure in rheumatoid arthritis patients. Ann Rheum Dis. 2015;74 (Suppl 2):481.